8 results
Treatment algorithm for VTE in Malignancy

(A) Suggested treatment algorithm for symptomatic and incidental DVT or PE
Treatment algorithm ... for VTE in Malignancy ... #DOAC #VTE #Malignancy ... Anticoagulation #Management ... #Hematology #Oncology
Patient risk stratification algorithm for the treatment of cancer-associated thrombosis.

Currently, edoxaban and rivaroxaban are the only
algorithm for the treatment ... #DOAC #VTE #Malignancy ... Anticoagulation #Management ... #Hematology #Oncology
â–º
Chronic Lymphocytic Leukemia (CLL) - Summary
Overview: 
 • Most common leukemia in adults
 • Disorder of
transformation) Treatment ... AIHA, PRCA) • Treatment ... Lymphocytic #Leukemia #oncology ... #hematology #hemeonc ... #diagnosis #management
Heparin Induced Thrombocytopenia (HIT) - Diagnosis and Management - GrepMed Handbook

Presentation: 
 • Plts ↓50% (nadir
Diagnosis and Management ... approach for post-test ... : Confirmatory test ... #Treatment #Hematology ... #HemeOnc
Giant cell arteritis (GCA)

Giant cell arteritis (GCA) definition: Most common systemic inflammatory vasculitis in older adults
vs infection vs malignancy ... the “Chewing gum test ... Treatment of GCA ... them, but urgent rheumatology ... Symptoms #Diagnosis #Management
Hodgkin's Lymphoma Overview

Hodgkin's lymphoma (HL) is an uncommon hematological malignancy arising from mature B cells. It
hematological malignancy ... Hodgkin Lymphoma Treatment ... classification #hematology ... #oncology #management
SAPHO Syndrome Summary

What?
SAPHO syndrome is a rare chronic inflammatory disorder of bone, joint, and skin characterized
as infectious, malignant ... and lower jaw Treatment ... blockers had the best ... SAPHO #Syndrome #Rheumatology ... #diagnosis #management
Hemophagocytic Lymphohistiocytosis (HLH)

High mortality without prompt recognition and management. HLH is a critical diagnostic consideration in
recognition and management ... search for and treatment ... Treatment Approach ... trigger: Infections, malignancy ... #Hematology #HemeOnc